Search research articles
Contact Us
Filters
Showing results (21-30 of 43) with videos related to
Page
of 5
Sort By:
Cancer
|
October 6, 2010
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer
Karen Reckamp, Barbara Gitlitz, Lin-Chi Chen, et al.
Investigational New Drugs
|
February 6, 2020
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
Geoffrey L Uy, Sarit Assouline, Anne-Marie Young, et al.
Cancer Chemotherapy and Pharmacology
|
May 8, 2019
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [<sup>14</sup>C]-labeled idasanutlin and an intravenous tracer dose of [<sup>13</sup>C]-labeled idasanutlin in a single cohort of patients with solid tumors
Zsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, et al.
Biosensors & Bioelectronics
|
May 15, 2004
Amperometric detection of morphine at a Prussian blue-modified indium tin oxide electrode
Kuo-Chuan Ho, Chia-Yi Chen, Huan-Cheng Hsu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 22, 2009
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer
Lin-Chi Chen, Andrew B Brown, Irene Y Cheung, et al.
ACS Applied Materials & Interfaces
|
April 22, 2016
Signal-on Protein Detection via Dye Translocation between Aptamer and Quantum Dot
Yeh-Hsing Lao, Chun-Wei Chi, Sarah M Friedrich, et al.
Cancer Chemotherapy and Pharmacology
|
January 26, 2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors
John Nemunaitis, Annie Young, Samuel Ejadi, et al.
Investigational New Drugs
|
November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
Albiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Chemical Communications (Cambridge, England)
|
June 20, 2012
Nanoporous carbons through direct carbonization of a zeolitic imidazolate framework for supercapacitor electrodes
Watcharop Chaikittisilp, Ming Hu, Hongjing Wang, et al.
Biosensors & Bioelectronics
|
August 4, 2019
Spectral contrast imaging method for mapping transmission surface plasmon images in metallic nanostructures
Ming-Yang Pan, Deng-Kai Yang, Chih-Yu Lai, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 43) with videos related to
Sort By:
Page
of 5
Cancer
|
October 6, 2010
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer
Karen Reckamp, Barbara Gitlitz, Lin-Chi Chen, et al.
Investigational New Drugs
|
February 6, 2020
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
Geoffrey L Uy, Sarit Assouline, Anne-Marie Young, et al.
Cancer Chemotherapy and Pharmacology
|
May 8, 2019
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [<sup>14</sup>C]-labeled idasanutlin and an intravenous tracer dose of [<sup>13</sup>C]-labeled idasanutlin in a single cohort of patients with solid tumors
Zsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, et al.
Biosensors & Bioelectronics
|
May 15, 2004
Amperometric detection of morphine at a Prussian blue-modified indium tin oxide electrode
Kuo-Chuan Ho, Chia-Yi Chen, Huan-Cheng Hsu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 22, 2009
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer
Lin-Chi Chen, Andrew B Brown, Irene Y Cheung, et al.
ACS Applied Materials & Interfaces
|
April 22, 2016
Signal-on Protein Detection via Dye Translocation between Aptamer and Quantum Dot
Yeh-Hsing Lao, Chun-Wei Chi, Sarah M Friedrich, et al.
Cancer Chemotherapy and Pharmacology
|
January 26, 2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors
John Nemunaitis, Annie Young, Samuel Ejadi, et al.
Investigational New Drugs
|
November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
Albiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Chemical Communications (Cambridge, England)
|
June 20, 2012
Nanoporous carbons through direct carbonization of a zeolitic imidazolate framework for supercapacitor electrodes
Watcharop Chaikittisilp, Ming Hu, Hongjing Wang, et al.
Biosensors & Bioelectronics
|
August 4, 2019
Spectral contrast imaging method for mapping transmission surface plasmon images in metallic nanostructures
Ming-Yang Pan, Deng-Kai Yang, Chih-Yu Lai, et al.
Page
of 5